Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Business Context and Reporting Period
Arcturus Therapeutics Holdings Inc. filed a Current Report on Form 8-K regarding an amendment to the loan agreement of its wholly owned subsidiary, Arcturus Therapeutics, Inc. The material event occurred on October 27, 2021; the filing was signed on November 1, 2021.
Material Financing Change
- Arcturus Therapeutics, Inc. entered into a Fifth Amendment to its Loan and Security Agreement with Western Alliance Bank.
- The borrower will make monthly interest-only payments through the payment date immediately preceding May 1, 2022.
- Beginning May 1, 2022, the borrower will make equal monthly principal and interest payments based on an 18-month repayment schedule.
- The filing does not provide the outstanding loan balance, interest rate, payment amounts, maturity date, fees, or collateral details.
Financial Metrics and Liquidity
The filing does not report revenue, profit, cash flow, margins, cash balances, debt balances, liquidity ratios, or other operating financial metrics. The amendment defers principal repayments until May 1, 2022, which may affect near-term cash requirements but increases scheduled debt-service obligations thereafter.
Outlook, Risks, and Unusual Items
No formal guidance or broader management outlook is provided. Key considerations include the company’s ability to fund the required principal and interest payments beginning in May 2022 and compliance with the amended loan terms. The complete Fifth Amendment was to be filed as an exhibit to the company’s Form 10-Q for the quarter ended September 30, 2021.
Facts Investors Should Verify
- Outstanding principal, applicable interest rate, and monthly payment amounts under the amended loan.
- Any covenants, events of default, collateral provisions, fees, or prepayment terms in the full Fifth Amendment.
- Cash and cash equivalents, operating cash burn, and available financing as of September 30, 2021.
- Whether the company expects sufficient liquidity to meet the 18-month amortization schedule beginning May 2022.